Nalbuphine
This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.
Peso molecular
357,4000 g/mol
LogP
0,20
TPSA
73,20 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …
Estructura 2D
Cite this structure
Embed this structure
SMILES
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
InChI
InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
Molecular Formula
C21H27NO4
HBD / HBA
3 / 5
Enlaces Rotables
2
Átomos Pesados
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This opioid pain medication is given by injection to relieve moderate to severe pain, including pain during surgery or in the post-operative period. It acts on opioid receptors in the brain and spinal cord to reduce pain perception while also having properties that can help reverse some side effects of other opioids.
Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.
Yes, Nalbuphine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL895. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5311304. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="nalbuphine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/nalbuphine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/nalbuphine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/nalbuphine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="nalbuphine"></drugfyi-drug>